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Introduction
Patient involvement is a key factor in the development
of treatment, hence in (pre) clinical trial design, choice
of primary and secondary endpoints, protocol set-up
etc. Including patient representatives in drug and treat-
ment development from A to Z as equal partners would
lead to a better and longer life for the patient.
Benefits
Patient involvement in clinical trial guarantees that the
drug or treatment tackles issues and problems patients
experience. The study design is patient centered, which
means closer to real life, better recruitment and less CT
drop out. Taking into account the burden CT’s put on
“normal life” for a person with a rare condition during
study set up and CT execution, improves the represen-
tativeness of the study and ensures that once the drug
or treatment is available to the patient “in real life”,
adherence is maximized. The result is a more effective
and efficient drug and treatment for the patient and
society.
Methods
Patients should be asked which drugs or treatment would
“by priority” benefit them, before the CT design is deter-
mined and what their needs are (for ex. Eurocare CF) in
general but also for every drug or treatment develop-
ment. Structured and systematic involvement of patients
in drug and CT development is required. Using different
tools (questionnaires, interviews, focus groups ) on a reg-
ular basis could help develop a structured, patients’
representatives view on their needs. Patients have a say in
defining for example what kind of care is needed; what
will improve their QOL, outcome and life expectancy;
what type of molecule, drug or treatment will do the
trick; what kind of trial(s) we need; which population is
targeted: adult and/or pediatric population; and what
type of administration of the molecule/drug is possible,
comfortable, can be fitted in daily life?
Conclusion
It is possible and necessary to involve patient representa-
tives in drug and treatment development, especially clini-
cal trials, on a European level. It should be considered
“good clinical practice” in design and implementation of
clinical trials to imbed the patients’ point of view (by
patient representatives) structurally, making it a legal obli-
gation if desired, in policy decisions regarding drugs and
treatment, in clinical trial networks, in pharmaceutical
companies wanting to develop a drug or treatment, and
others.
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